Kornimate/medical-research-clean huggingface dataset:
the effect of hot pack application on postoperative ileus undergoing surgery for gynecologic malignancies

Conditions: Postoperative Ileus

Summary: postoperative ileus (poi), is an extensively known complication characterized by an impairment of normal gastrointestinal motor activity after abdominal surgery and may also occur after surgery at other sites due to non-mechanical causes. \[1\]. this clinical asset has been linked to prominent perioperative morbidity with the following financial burden owing to extended hospitalization \[1\]. furthermore, poi can postpone adjuvant treatments, such as chemotherapy in patients who went through surgery for cancers. abdominal tenderness and distension, nausea and vomiting, delay in the passage of flatus and stool, and intolerance to solid food are the prime symptoms of poi \[1-3\]. it is generally transient, but if prolonged, can cause surgical incision dehiscence, intestinal anastomotic fistula, abdominal cavity infection, intestinal ischemia, aspiration pneumonia, and other serious complications \[4-6\]. hence, many clinicians have focused on averting poi. many studies have analyzed preventive methods, such as preoperative mobilization of the patient, adequate pain control, gum chewing, epidural anesthesia, coffee consumption, and motility agents such as metoclopramide and alvimopan \[7-15\]. for all the manifold remedy approaches, poi maintains a difficult clinical challenge that compromises the rapid improvement of patients who underwent abdominal surgery. recently, thermal attempts have been employs for several situations such as inflammatory bowel disease, chronic pelvic pain, and abdominal pain \[16\]. it may be used in two different ways; whole body or local. local thermal therapy can be carried out by hot pack or paraffin \[17\]. it has been demonstrated that local thermotherapy abate myotonia, enhances circulation, and eases pain by expediting the removal of the pain-producing substance. local thermal therapy is widely used for a number of conditions such as pain, nausea, vomiting, and some bowel diseases in traditional chinese medicine \[18\].


Eligibility criteria:
inclusion criteria: * patiens aith aged ≥18 years olds * patients undergoing elective exhaustive staging surgery (total hysterectomy (type a-c2), systematic pelvic para-aortic lymphadenectomy ± bilateral salpingo-oophorectomy and ± omentectomy by abdominal approach containing either open or laparoscopic surgery. exclusion criteria: * asa score \>3, * chronic constipation (defined as ≤2 bowel movements per week), * inflammatory bowel disease, * irritable bowel syndrome, * compromised liver function, * clinically significant cardiac arrhythmia, * thyroid disorder, * history of abdominal bowel surgery, * previous abdominal irradiation, * previous neoadjuvant chemotherapy or hyperthermic intraperitoneal chemotherapy, * performed upper abdominal surgery * the covid-19 positive test result, * bowel anastomosis.
study comparing standard dose and high-dose imatinib mesylate in patients with chronic phase philadelphia chromosome positive (ph+) chronic myelogenous leukemia (cml)

Conditions: Chronic Myelogenous Leukemia

Summary: the study will assess the role of high-dose imatinib mesylate, in patients who have taken imatinib mesylate for at least 1 year at the standard dose, in achieving a major molecular response (a measure of the level of chronic myelogenous leukemia) versus the standard dose.


Eligibility criteria:
inclusion criteria: * chronic myelogenous leukemia with philadelphia chromosome * 18 years and older * patients must have been taking imatinib mesylate standard dose for at least 12 months and have achieved a complete cytogenetic response but not a major molecular response. exclusion criteria: * patients with cardiac problems such as congestive heart failure, or myocardial infarction within the last 6 months * patients with an uncontrolled medical disease such as uncontrolled diabetes, chronic renal (kidney) disease or active uncontrolled infection. * patients with other current primary malignancy or malignancy requiring active intervention other protocol defined inclusion/exclusion criteria may apply.

Keywords: chronic myelogenous leukemia complete cytogenetic response imatinib mesylate major molecular response chronic phase ph+ chronic myelogenous leukemia
safety, tolerability and pk of azd1152 in patients with relapsed acute myeloid leukaemia (aml)

Conditions: Acute Myeloid Leukaemia

Summary: the purpose of this study is to assess safety and tolerability of multiple ascending doses of azd1152 and to assess effect of azd1152 on the rate of complete remission in patients with relapsed acute myeloid leukaemia who are not considered to be suitable for standard chemotherapy.


Eligibility criteria:
inclusion criteria: * patients with relapsed or refractory aml for which no standard therapies are anticipated to result in durable remission * newly diagnosed acute myeloid leukemia who are not considered suitable for other treatments. exclusion criteria: * administration of anticancer agents (other than hydroxyurea) within 2 weeks prior to first dose of study drug, and administration of hydroxyurea within 24 hours prior to first dose of study drug * participation in any other trial with an investigational product within the previous 30 days. * uncontrolled intercurrent illness including, but not limited to, active infection, symptomatic congestive heart failure, cardiac arrhythmia or psychiatric illness/social situations

Keywords: acute myeloid leukaemia phase 1 azd1152
tecovirimat for treatment of monkeypox virus

Conditions: Monkeypox

Summary: the purpose of this study is to find out if tecovirimat is a safe and effective drug to treat monkeypox (mpox) in combination with standard of care (soc). participants will be randomly assigned to receive oral tecovirimat plus soc or placebo plus soc for 14 days.

this is a randomized, placebo-controlled, double-blind study to test the antiviral drug tecovirimat for the treatment of adults and children with laboratory-confirmed monkeypox virus (mpxv) disease at participating sites in the democratic republic of congo. eligible and consented participants will be randomized 1:1 to receive either oral tecovirimat or placebo, each administered in the hospital with standard-of-care (soc) treatment for 14 days. participants will be followed for 28 days with an optional visit at day 59 for long-term assessment. if a participant reaches full body lesion resolution but subsequently develops at least one new lesion consistent with mpox after discharge but while still enrolled in the study, they will be eligible to make a sick visit and will be offered standard of care for mpox.

Eligibility criteria:
this study has no age restriction. inclusion criteria: * laboratory-confirmed monkeypox virus infection as determined by pcr obtained from blood, oropharynx, or skin lesion within 48 hours of screening * monkeypox illness of any duration provided that the patient has at least one active, not yet scabbed, lesion * weight ≥3 kg * men and non-pregnant women of reproductive potential must agree to use effective means of contraception when engaging in sexual activities that can result in pregnancy, from the time of enrollment through the end of study participation. acceptable methods of contraception include the following: * hormonal contraception * male or female condom * diaphragm or cervical cap with a spermicide * intrauterine device * stated willingness to comply with all study procedures (including required inpatient stay) and availability for the duration of the study * ability to provide informed consent personally or by a legally or culturally acceptable representative if the patient is unable to do so exclusion criteria: * current or planned use of a meglitinide (repaglinide, nateglinide) * planned use of midazolam while on study drug * severe anemia, defined as hemoglobin \<7 g/dl * current or planned use of another investigational drug at any point during study participation * patients who, in the judgement of the investigator, will be at significantly increased risk as a result of participation in the study * participants who are unable to safely swallow oral medications, such as those who are at risk of aspiration

Keywords: monkeypox mpxv
wemr with clinical decision support for all wounds

Conditions: Chronic Wounds

Summary: the goal of this project to begin using a wound research database with clinical decision support features at winthrop university hospital. a research database is an electronic computer system that is used to collect patient information. clinical decision support is the ability for a computer system to provide medical assistance to the doctor through alerts and recommendations based on the information entered. the investigators believe that use of a wound clinical decision support tool, much like a drug, will improve healing in patients with chronic wounds (wounds that fail to heal over the course of weeks) and ultimately lower the risk of death and illness caused by these wounds. in order to develop a useful clinical decision support tool, investigators first need to develop a large research database to determine the data points important for wound healing. the investigators will be using the data collected in this study for future research and publication. data will be reviewed to answer questions important to wound healing and for the purpose of developing the clinical decision support alert system. after providing informed consent, participants will be asked a series of questions related to their past medical history, and relevant wound data will be collected. study staff will photograph the wound at baseline, and once per week until the wound is completely healed, or for a duration of six months. participants will be expected to return to winthrop university hospital for wound follow-up on a regular basis, or as determined by the principal investigator.


Eligibility criteria:
inclusion criteria: * 21 years or older * diagnosed with a wound (defined as a break in the integument) * must be willing and able to provide written informed consent exclusion criteria: * patients with diabetic foot ulcers

Keywords: wound wound healing pressure ulcers chronic wounds clinical decision support
study to evaluate the efficacy, safety, and tolerability of sarecycline for treating periorificial dermatitis

Conditions: Perioral Dermatitis

Summary: a single-center pilot study to evaluate the efficacy, safety, and tolerability of sarecycline for treating periorificial dermatitis

this pilot study's intended purpose is to evaluate the efficacy, safety, and tolerability of sarecycline for periorificial dermatitis. sarecycline, a third-generation tetracycline, is currently only indicated to treat acne vulgaris. however, the investigator has used sarecycline to treat periorificial dermatitis and would like to capture and report on this efficacy in a pilot study. the investigator hypothesize's that not only will the subjects respond well to sarecycline treatment, but that it will be well-tolerated.

Eligibility criteria:
inclusion criteria: * have a clinical diagnosis of pod by both the principal investigator and a blinded observer * have a podsi score of 3.0 or greater at baseline by clinical investigator * must not be dysphagic. * patient is male or female, 18-55 years of age inclusive at screening. exclusion criteria: * allergy to tetracyclines. * immunocompromised. * pregnancy or planning a pregnancy during the study period. * lactating subjects. * ongoing use of any of the following treatments to the face throughout study; oral or topical steroids, oral or topical calcineurin inhibitors, topical retinoids, topical antibiotics, - oral or topical metronidazole, or topical azelaic acid. * facial hair or skin dermatoses that interfere with evaluation of the perioral dermatitis.
testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel (trigger-pci)

Conditions: Coronary Artery Disease (CAD)

Summary: to determine the efficacy of prasugrel versus clopidogrel for the reduction of adverse cardiovascular outcomes in patients with high platelet reactivity on clopidogrel after successful implantation of coronary drug-eluting stents. to determine the adverse event profile of prasugrel in patients with high platelet reactivity on clopidogrel after implantation of coronary drug-eluting stents. to determine the effect of prasugrel on inhibition of platelet activation in patients with high platelet reactivity on clopidogrel.


Eligibility criteria:
key inclusion criteria: * have coronary artery disease and clinical indication for percutaneous coronary intervention (pci) with implantation of at least one drug-eluting stent and where percutaneous coronary intervention of all treated lesions is successful. * have been given standard-of-care clopidogrel 600-mg loading dose between 24 hours before and at the time of pci. * standard of care aspirin use prior to pci - at least 250-mg \[intravenous (iv) or oral\] within 24 hours before pci and at the time of pci. * verifynow p2y12 reaction units \> 208 measured 2-7 hours after clopidogrel maintenance dose the day after successful pci. exclusion criteria: * non-st segment elevation myocardial infarction within 14 days prior to randomization * st-segment elevation myocardial infarction within 14 days prior to randomization * have known major complications after percutaneous coronary intervention and prior to randomization * have a body weight \< 60 kilogram (kg) * have cardiogenic shock at time of randomization * have refractory ventricular arrhythmias * have new york heart association class iv congestive heart failure * have received glycoprotein (gp) iib/iiia inhibitors eptifibatide or tirofiban within 24 hrs before or during percutaneous coronary intervention or abciximab within 10 days before or during percutaneous coronary intervention * are receiving daily treatment with nonsteroidal anti-inflammatory drug (nsaids) or cyclooxygenase-2 (cox2) inhibitors that cannot be discontinued or are anticipated to require \> 2 weeks of daily treatment during the study

Keywords: clopidogrel verifynow pru measurements drug eluting stents (des) heart disease percutaneous coronary intervention (pci) p2y12 platelets platelet reactivity
multiplex testing for evaluation of breast cancer risk, longitudinal study

Conditions: BRCA1/2 Negative

Summary: the overall goal of the proposed research is to evaluate the uptake of testing and longitudinal risks and benefits of multiplex testing for cancer susceptibility in brca1/2 negative patients. this model will inform the selection of the outcomes and potential mediators and moderators of these outcomes, to inform the debate over utility, risks, and benefits of clinical incorporation of multiplex testing for breast cancer susceptibility.


Eligibility criteria:
inclusion criteria: * 1. women and men (at least 18 yo) 2. english speaking and 3. negative for brca1 and brca2 mutations exclusion criteria: 1. non english speaking patients

Keywords: patients
efficacy and safety of 14-day concomitant therapy for helicobacter pylori infection

Conditions: Helicobacter Pylori Infection

Summary: the purpose of this study is to evaluate efficacy of a 14-day concomitant therapy for the third-line treatment of helicobacter pylori infection, and whether it is safe while maintaining an ideal eradication rates.

helicobacter pylori infects half of the world's population. h.pylori eradication is an effective approach to reduce the risk of developing gastric cancer. however, eradication rates of first-line therapy decreased over years due to the rapidly increasing antibiotic resistance of h. pylori worldwide. an ideal rescue therapeutic regimen to cure refractory h.pylori infection is currently warranted. few published paper evaluated the efficacy of 14-day furazolidone containing concomitant therapy in the third line treatment. this study aims to propose a new concomitant therapy for the patients with two or more treatment failure, and then evaluates whether adverse effects are tolerable. .

Eligibility criteria:
inclusion criteria: * patients aged 18-70 with persistent h. pylori infection. * patients failed at least three different standard eradication therapies before. previous standard eradication therapy was defined as a 10-day or 14-day quadruple regimen designed according to maastricht v report. exclusion criteria: * patients unable or unwilling to receive gastroscopy. * patients treated with h2-receptor antagonist, ppi, bismuth and antibiotics in the previous 4 weeks. * patients with gastorectomy, acute gi bleeding and advanced gastric cancer. * history of allergy to any of the drugs used in the study. * severe concomitant cardiovascular, respiratory, or endocrine diseases, clinically significant renal or hepatic disease, hematologic disorders and any other clinically significant medical condition that could increase risk. * currently pregnant or lactating. * severe neurologic or psychiatric disorders. * alcohol abuse or drug addiction. * patients with compliance lower than 90% in any previous treatment are not included. * inability to provide informed consent and other situations that could interfere with the examination or therapeutic protocol.

Keywords: concomitant therapy rescue treatment
the effect of air pollution on lung health among school children living in haifa bay region

Conditions: Bronchial Asthma; Signs and Symptoms, Respiratory; Allergy

Summary: haifa bay region is located close to a major industrial zone. the aim of the study is to evaluate the health status of school children living in haifa bay region.the health status will be evaluated using health questionnaires and spirometry.

haifa bay is located close to a major industrial zone. the aim of the study is to evaluate the health status of children living in haifa bay region. the health status will be evaluated while using health questionnaires and spirometry. objective: to evaluate the respiratory health of haifa bay region children with comparatives, with respect to local air pollution levels. material and methods: children from haifa bay region from 10 different communities (1200 children) will be included in the study, after both parents and the children (above 12 years of age) will sign an informed consent form. first step: a health questionnaire (based on hebrew version of isaac questionnaire) will be filled in by the parents. second step: spirometry checking of the children. in parallel, air pollution levels will be measured and provided by a network of ground monitoring stations maintained by the haifa district municipality association for the environment (hdmae). the station provides half-hourly measurement of mean concentrations of gaseous (nox, so2, o3) and particular (pm 10) pollutants over the entire investigation window. additional meteorological data are also collected. risk maps: using a gis platform, we are developing a multi-layer risk mapping procedure which accounts for ambient concentrations of selected pollutants and the heterogenic spatial distribution of several demographic and socio-economic indexes in the region. the prevalence of pulmonary disease will be evaluated according to the risk maps the health status of the children will be documented from the children's primary clinic files as well.

Eligibility criteria:
inclusion criteria: * living in haifa bay region, israel. * parents signed informed consent. exclusion criteria: * children that their parents did not signed the informed consent * chronic disease except of asthma: diabetes mellitus, cystic fibrosis, cardiac diseases, renal, rheumatic and chronic gastrointestinal diseases, mental retardation.

Keywords: asthma allergy respiratory pollution children air pollution
comparing nicobloc to nicotine lozenges

Conditions: Smoking Cessation; Nicotine Dependence

Summary: to examine the feasibility, acceptability, and preliminary impact of using nicobloc compared to nicotine lozenges

smoking remains the leading cause of preventable death in the u.s. with approximately 18% of the population continuing to smoke. however, smoking is concentrated in disadvantaged populations where the prevalence of smoking may be as high as 70-80 %. participants will receive a sampling experience (use of nicotine lozenges or nicobloc during sessions) with counseling focused around their experience of using these interventions, including side effects and smoking cessation expectancies.

Eligibility criteria:
inclusion criteria: 1. 18 years or older 2. planning to live in the birmingham metro area for the next 3 months 3. smoking at least 5 cigarettes per day for the past year and a carbon monoxide\>8ppm to ensure daily smoking. this relatively low cutoff was chosen due to the expectation of enrolling a large \>50% african-american average \<10 cigarettes per day compared to whites who average \~15 cigarettes per day 4. exclusive use of filtered cigarettes 5. english speaking. exclusion criteria: 1. living in a restricted environment that does not allow smoking (e.g., prison or jail facility, etc.) 2. pregnant or nursing (all women of childbearing potential will be required to use an acceptable form of contraception) 3. currently enrolled in a smoking cessation treatment program, using nicotine replacement products, or prescribed bupropion or varenicline 4. known allergy nicotine lozenge 5. within one month post-myocardial infarction or untreated severe angina 6. cognitive impairment or unstable psychiatric condition that interferes with the informed consent process (individuals stable on psychiatric medications will be included) 7. daily or exclusive use of other tobacco products (e.g., electronic cigarettes, little cigars, etc.).
effects of omega 3 in hemodialysis patients

Conditions: Hemodialysis; End Stage Renal Disease

Summary: the aim of the study was to determine the effects of a 3-week fish oil oral supplementation on the metabolic fate and thermogenic effect of an oral glucose load in hemodialysis patients.


Eligibility criteria:
inclusion criteria: * hemodialysis at least 6 months duration end stage renal disease exclusion criteria: * - age \ 75 y * hemodialysis \< 6 months * diabetes, obesity * allergy to fish * asthma * glucocorticoïds, propranolol,, immunosuppressive drugs, insulin, somatostatin * erythropoïetin \< 3 months * cancer * hemoglobin \< 11 g/l * disease \< 1 month * pregnancy * respiratory insufficiency * intensive sport practice * refusal

Keywords: nutrition omega 3 fatty acids insulin resistance